Inclusion Criteria:

          -  Adults (≥18 years) with histologically or cytologically-confirmed advanced
             unresectable or metastatic melanoma. BRAF mutation-positive and wild-type tumors are
             allowed.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Adequate hematologic, renal, and hepatic function

          -  Life expectancy ≥12 weeks

          -  Any pre-existing neuropathy must be <grade 2 per Common Technology Criteria for
             Adverse Events (CTCAE) version 4.0

        Exclusion Criteria:

          -  More than 1 prior cytotoxic chemotherapy regimen in the metastatic setting

          -  Prior MEK inhibitor therapy (prior BRAF inhibitor allowed)

          -  Prior nab-paclitaxel (prior taxane allowed)

          -  Use of an investigational anti-cancer drug within 21 days or 5 half-lives (whichever
             is shorter) prior to first dose. A minimum of 10 days after termination of
             investigational drug is required. Any drug-related toxicity should have resolved to
             Grade 1 or baseline.

          -  Symptomatic or untreated brain metastases

          -  History of retinal vein occlusion (RVO)